Targapremir-210 ≥98%
促销价¥{{model.attbuying.price}}
市场价¥0.00
累计销量0 累计评价0 人评论
-
{{item.title}}
| 包装规格: | 1mg 5mg in glass bottle |
| 溶解性: | 溶于DMSO(250 mg/mL 超声) |
| 产品描述: | 基本信息 产品编号:T10719 产品名称:Targapremir-210 CAS: 1049722-30-6 储存条件 粉末 -20℃ 四年 分子式: C32H36N10O2 溶于液体 -80℃ 六个月 分子量 592.69 -20℃ 一个月 化学名: Solubility (25°C) 体外 DMSO Ethanol Water 体内(现配现用) <1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 制备储备液 浓度 溶液体积 质量 1mg 5mg 10mg 1mM 1.6872mL 8.4361mL 16.8722mL 5mM 0.3374mL 1.6872mL 3.3744mL 10mM 0.1687mL 0.8436mL 1.6872mL 生物活性 产品描述 一种有效的、选择性的 miR-210 抑制剂。 靶点/IC50 IC50: 200nM (miR-210, in MDA-MB-231 cells) 体外研究 Targapremir-210 decreases mature miR-210 levels in MDA-MB-231 cells cultured under hypoxic conditions, with an IC50 of -200nM.Targapremir-210 (200nM) induces MDA-MB-231 cells apoptosis is selective for the hypoxic environment.Targapremir-210 induces cells apoptosis under hypoxic conditions and does not induce apoptosis in MDA-MB-231 cells cultured in normoxia. 体内研究 Targapremir-210 (100μL of 200nM; single i.p. injection) impedes MDA-MB-231 triple negative breast cancer (TNBC) cells proliferation in vivo. Targapremir-210 is able to reach the tumor and sustain for the entire 21-day period, and decreases tumor burden in a TNBC mouse model. Animal Model: NOD/SCID mice were subcutaneously transplanted cell suspension into breast fat pads Dosage: 100μL of 200nM Administration: Single i.p. injection 24h post-transplantation Result: Decreased tumor growth as assessed by luciferase signal intensity and mass of the resected tumor. |
| 保存条件: | -20℃ |
-
蜀牛玻璃三角瓶
¥85.00 销量:16
-
15mL锥底离心管,袋装灭菌,橙色盖
¥636.00 销量:12
-
UFC5030BK 超滤管[0.5ml 30KD]
¥52.00 销量:10
-
UFC5010BK 超滤管[0.5ml 10KD]
¥52.00 销量:10
-
20×TBST缓冲液
¥130.00 销量:10
-
10mL移液管,易撕型全塑包装
¥456.00 销量:10
-
¥158.00
通用型 DNA 纯化回收试剂盒 -
¥158.00
质粒快速小提试剂盒 -
¥828.00
100mm TC细胞培养皿,袋装灭菌

